ImmunityBio Inc. faces mounting pressure as pivotal clinical trial setbacks overshadow prospects, with stocks have been trading down by -8.29 percent.
Click Here for a Millionaire's POV on Trading IBRX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Director Cheryl Cohen sold 131,210 shares of ImmunityBio Inc. for roughly $1.25M, per a Form 4 filing with the SEC on 2026/07/07.
- After the sale, Cohen still holds 125,386 IBRX shares, keeping meaningful exposure to ImmunityBio’s future.
- The insider sale lands as IBRX trades in a tight $8–$9 range after a strong multi-week run.
- Heavy losses and rich valuation keep ImmunityBio Inc. in high-risk territory despite a strong balance sheet.
Live Update At 12:33:07 EDT: On Friday, July 10, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending down by -8.29%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
IBRX has been grinding higher for weeks, but the tape is starting to cool off. From 2026/06/15 to 2026/07/02, ImmunityBio Inc. ran from around $7.13 to a closing high of $9.44, a sharp upside move for a biotech name this speculative. Since then, the daily chart shows IBRX stuck mostly between $8.50 and $9.00, with the latest close near $8.14 after fading off an $8.92 open.
Intraday, the 5‑minute chart shows a classic fade day. IBRX opened strong near $8.90, flushed quickly into the low $8.30s, then spent the rest of the session chopping between $8.06 and $8.22. That kind of action tells traders momentum is stalling and dip-buyers are less aggressive.
More Breaking News
- HTZ Stock Draws Traders After $350M Debt Deal
- OPEN Stock Pulls Back As Traders Weigh Cash, Losses
- ALM Stock Gains Attention As Tungsten Security Story Accelerates
- LX Stock Drops As Selling Pressure Hits North Asia Fintech Name
Financially, ImmunityBio Inc. is still deep in development-mode. Over the last quarter, IBRX generated about $44.2M in revenue but booked a net loss of roughly $632.8M and EBITDA around -$614.5M. Margins are massively negative, asset returns are deeply in the red, and the price-to-sales ratio near 51.8 signals a very expensive story stock. The bright spot: IBRX holds over $205M in cash, a current ratio of 6.7, and working capital around $385M, giving the company runway but not erasing the burn risk.
Why Traders Are Watching Insider Activity At IBRX
What pulled IBRX back on traders’ radar this week was not a trial headline or an FDA update. It was insider selling. A Form 4 filed with the SEC shows ImmunityBio Inc. director Cheryl Cohen sold 131,210 shares of IBRX for about $1.25M, while still keeping 125,386 shares.
Insider sales always get attention in speculative biotech. Traders know management and directors see the operational realities up close, so when a board member unloads a large block, short-term sentiment often turns cautious. With IBRX already priced like a big win is coming — remember that rich price-to-sales multiple above 50x on barely $113.3M in trailing revenue — any hint of reduced insider exposure can nudge momentum players to lock in gains.
But context matters. Cohen did not exit ImmunityBio Inc.; she cut roughly half her position and left a sizable stake on the table. That tells traders this is not a full vote of no confidence. It looks more like risk management or diversification, which is normal after a strong run in IBRX.
On the chart, the timing lines up with the consolidation phase. IBRX sprinted from the mid‑$6s to the mid‑$9s in a few weeks, then started to chop sideways just as this insider sale hit the tape. Short‑term traders will see that as a potential inflection point: either IBRX finds support around $8 and builds a new base, or selling pressure from profit‑takers and nervous longs pushes it back toward prior support in the low‑$7s. Watching volume around any test of those levels will be key.
Conclusion
For active traders, IBRX sits at one of those classic crossroads. ImmunityBio Inc. has strong liquidity for now, with more than $200M in cash and a fat current ratio. At the same time, the company is bleeding money, posting huge operating losses and deeply negative returns on assets. The valuation assumes big future success even though that success is not guaranteed.
Layer the Cheryl Cohen sale on top of that, and you get a more fragile sentiment setup. A director turning 131,210 IBRX shares into roughly $1.25M cash while keeping 125,386 shares sends a mixed but important message. She is dialing down exposure, not walking away from ImmunityBio Inc. entirely. Traders should read that as a yellow light, not a red one.
This is where trading discipline matters. IBRX is a momentum and story name, not a stable cash cow. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” The daily and intraday charts show a stock that ran hard and is now pausing while insiders trim. In the words of Tim Sykes, “The market doesn’t care about your opinion, only your discipline — cut losses quickly and let the best setups prove themselves.” For anyone studying IBRX, that means respecting the risk, letting price action confirm direction, and always treating this analysis as educational and research material — never as a signal to buy or sell.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.